Back to News
Market Impact: 0.25
SueWallSt Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026
Source: globenewswire.com
Legal & LitigationHealthcare & Biotech
A securities class-action lawsuit has been filed against Aardvark Therapeutics on behalf of investors who purchased AARD shares between February 13, 2025 and May 14, 2026. The notice provides no allegations, claimed damages, or potential financial exposure, but the litigation introduces legal and reputational risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AARD-0.85
More News
- Bloomberg Law: No Breakup of Google & Clippers Fined (Podcast)
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026
- Meta Platforms Settles Major Lawsuit, Pays $18 Billion